Clinical Validation of a Novel T-Cell Receptor Sequencing Assay for Identification of Recent or Prior Severe Acute Respiratory Syndrome Coronavirus 2 Infection

التفاصيل البيبلوغرافية
العنوان: Clinical Validation of a Novel T-Cell Receptor Sequencing Assay for Identification of Recent or Prior Severe Acute Respiratory Syndrome Coronavirus 2 Infection
المؤلفون: Sudeb C Dalai, Jennifer N Dines, Thomas M Snyder, Rachel M Gittelman, Tera Eerkes, Pashmi Vaney, Sally Howard, Kipp Akers, Lynell Skewis, Anthony Monteforte, Pamela R Witte, Cristina Wolf, Hans Nesse, Megan Herndon, Jia Qadeer, Sarah Duffy, Emily Svejnoha, Caroline Taromino, Ian M Kaplan, John Alsobrook, Thomas Manley, Lance Baldo
المصدر: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 75(12)
سنة النشر: 2021
مصطلحات موضوعية: Microbiology (medical), Infectious Diseases, COVID-19 Testing, SARS-CoV-2, Clinical Laboratory Techniques, Receptors, Antigen, T-Cell, Humans, COVID-19, Prospective Studies, Sensitivity and Specificity, Retrospective Studies
الوصف: Background While diagnostic, therapeutic, and vaccine development in the coronavirus disease 2019 (COVID-19) pandemic has proceeded at unprecedented speed, critical gaps in our understanding of the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remain unaddressed by current diagnostic strategies. Methods A statistical classifier for identifying prior SARS-CoV-2 infection was trained using >4000 SARS-CoV-2–associated T-cell receptor (TCR) β sequences identified by comparing 784 cases and 2447 controls from 5 independent cohorts. The T-Detect COVID (Adaptive Biotechnologies) assay applies this classifier to TCR repertoires sequenced from blood samples to yield a binary assessment of past infection. Assay performance was assessed in 2 retrospective (n = 346; n = 69) and 1 prospective cohort (n = 87) to determine positive percent agreement (PPA) and negative percent agreement (NPA). PPA was compared with 2 commercial serology assays, and pathogen cross-reactivity was evaluated. Results T-Detect COVID demonstrated high PPA in individuals with prior reverse transcription–polymerase chain reaction (RT-PCR)–confirmed SARS-CoV-2 infection (97.1% 15+ days from diagnosis; 94.5% 15+ days from symptom onset), high NPA (∼100%) in presumed or confirmed SARS-CoV-2 negative cases, equivalent or higher PPA than 2 commercial serology tests, and no evidence of pathogen cross-reactivity. Conclusions T-Detect COVID is a novel T-cell immunosequencing assay demonstrating high clinical performance for identification of recent or prior SARS-CoV-2 infection from blood samples, with implications for clinical management, risk stratification, surveillance, and understanding of protective immunity and long-term sequelae.
تدمد: 1537-6591
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a49337cc5bf1a6559ab41e9b7c5888a
https://pubmed.ncbi.nlm.nih.gov/35521791
Rights: CLOSED
رقم الانضمام: edsair.doi.dedup.....0a49337cc5bf1a6559ab41e9b7c5888a
قاعدة البيانات: OpenAIRE